INTRODUCTION AND AIM: Symptom palliation is important in terms of improving quality of life and therapy compliance in patients diagnosed with lung cancer. In this study, we intend to describe the tumor symptoms and related factors with Edmonton Symptom Assessment Scale (ESAS) in patients who admitted to a palliative care unit.
Introduction
E limination of malignancy-related physical or emotional symptoms of these patients improves the social life quality and treatment compliance.
Describing the symptoms is the first step in starting malignancy treatment. [1] Advanced stage lung cancer is associated with many symptoms affecting the quality of life (QoL) of patients and has an important role in determining treatment options. Palliative care includes a wide range of treatment options aimed at improving survival and symptom palliation in patients with lung cancer. Various scoring systems are used to determine the symptom burden and severity of patients with malignancy. [2] Edmonton Symptom Assessment Scale (ESAS) is a simple, validated test used for this purpose. [3] High ESAS score correlates with disease burden and is important in symptom management. [4] ESAS is a test that needs to be applied as a standard in lung cancer treatment management. [5] Increasing frequency and severity of symptoms is related to poorer prognosis in patients with lung cancer. [6] Hence, management of palliation should be started from diagnosis and last during treatment period.
In this study, we intend to describe the tumor symptoms and related factors with ESAS in patients who admitted to a palliative care unit (PCU).
Materials and Methods
Two hundred and ninety patients with lung cancer were retrospectively reviewed. Patients with lung cancer who admitted to the outpatient clinic of PCU before any treatment were included. Patients' demographic parameters, tumor-node-metastasis (TNM) stages, and treatment protocols were collected from the hospital database or patients' files. Diagnosis was confirmed by pathologically/cytological. Positron-emission tomography-computed tomography (PET-BT) scan and cranial magnetic-resonance imaging were used for staging. (7 th edition of TNM was used).
ESAS is a measure evaluating ten symptoms that are common in cancer patients. The severity of each symptom is assessed by numeric numbers from 0 to 10. Zero points indicate no symptoms and 10 points indicate that the symptoms feel very severe, and the severity of the symptoms increases from 0 to 10. ESAS was applied to each patient at the onset of treatment to evaluate the initial symptoms of the patients. The results were recorded for all patients before starting treatment. [7] After detecting the most disturbing symptom by ESAS, palliative treatments were applied to patients in outpatient treatment unit or inpatient service. In following visits response to palliative treatments were assessed individually. But as a limitation, ESAS after treatment was not recorded.
Primary end-point is to detect most disturbing symptoms related to the lung cancer stage and comorbidities of patients. The mean Edmonton symptom score did not differ between patients with bone metastasis and without (P > 0.05). There was no significant difference between disease stage and mean ESAS, whereas in Stage IV group, the mean score for sleep variance was significantly higher than in all other stages (P = 0.038).
Statistical analysis
The parameters with highest score for each stage are described in Table 2 . Among locally advanced and advanced patients, tiredness and appetite were most disturbing symptoms [ Table 2 ].
Early and locally advanced stage patients (n = 120) were assessed in terms of lymph node positivity. Among these patients, 86 of them had pathological lymph node involvement and the scores of cough and how they felt themselves were significantly higher than patients with N0 (P = 0.016 and P = 0.027 respectively). Treatment modalities were divided into two groups: Group 1: best supportive care (BSC) (n = 22) and Group 2: others (n = 268) (systemic chemotherapy, palliative or curative radiotherapy, chemoradiotherapy, and operation). In Group 2, distribution of patients was nonhomogeneous, so they have gathered in a group. There was no statistically significant difference in terms of ESAS scores between patients receiving only supportive care and all other groups (P > 0.05) [ Table 3 ].
Patients with diabetes mellitus had higher scores for sadness and anxiety variable (P = 0.046 and P = 0.023, respectively).
The overall survival and mean ESAS score were not related (P > 0.05) [ Figure 1 ]. When analyzed in terms of each of ESAS parameters, even none of them had significant relation, but only the question of "how do you feel" had highest (P = 0.07).
Discussion
Although many symptoms can be seen in patients with lung cancer, pain, shortness of breath, and fatigue are the most common of them and these impair the QoL of the patients. [8, 9] ESAS focuses on most disturbing symptoms and guides the physicians about the treatment. [10] Even our study population is heterogeneous similar to the existing studies, majority of patients were male, in sixth decade and diagnosed in locally advanced and advanced stages. [11, 12] In the current study, because it is a common cause for pain and poor medical condition, bone metastasis was evaluated individually and there was no relation between the mean ESAS score and existence of bone metastasis. [13] Sleep disorders can be observed due to anxiety disorder in patients with lung cancer, and regular psychologist interviews can be helpful in PCUs for these patients. [14, 15] In the current study, the mean score for sleep variant of ESAS was observed statistically higher in Stage IV patients, and regular psychologist supports are being held in our clinic. There was no significant difference between ESAS parameters, but among locally advanced and advanced patients, tiredness and appetite were most disturbing symptoms. According to a study assessing the symptom burden of NSCLC, majority of patient-reported symptoms revealed a difference between Stage IIIB and Stage IV lung cancer. [16] According to a study with 182 advanced stage cancer patients by giving outpatient palliative care, a significant improvement was obtained in ESAS, especially in patients with moderate-to-severe symptoms. Thus, our data revealed no significant difference between patients receiving only supportive care and all other groups. In our opinion, this finding is a result of providing palliative care at the beginning of cancer diagnosis. [17] It was observed that having ESAS≥7, had a negative impact on the patients' physical, social, and emotional function. [18] Unsurprisingly, cough was associated with poor prognosis. [11] Lymph node positivity was related to a higher score for parameters of coughing and how they felt themselves.
ESAS is a useful tool for the screening of depression and anxiety in cancer patients without ideal cutoff value. [19] To the best our knowledge, there is no data investigating ESAS and comorbidities together in lung cancer. ESAS can be helpful to determine the comorbidities. According to our study, the presence of DM increased the level of sadness and anxiety scores significantly.
In our study, the overall survival and mean ESAS score were not related. Advanced stage NSCLC patients have been shown that early palliative treatment is related to better survival.
[11]
Conclusion
Regardless of cancer treatment protocol (including BSC) in all stages of lung cancer, symptom palliation should start at the time of diagnosis to end of life to improve patients' treatment compliance and physical, social, and emotional status. In addition, existence and appropriate management of comorbidities should be considered during malignancy treatment.
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